We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Halozyme Therapeutics Inc (HALO) Common Stock USD0.001

Sell:$45.70 Buy:$45.71 Change: $0.35 (0.76%)
NASDAQ:0.03%
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$45.70
Buy:$45.71
Change: $0.35 (0.76%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$45.70
Buy:$45.71
Change: $0.35 (0.76%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Contact details

Address:
12390 EL CAMINO REAL
SAN DIEGO
92130
United States
Telephone:
+1 (858) 7948889
Website:
https://www.halozyme.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HALO
ISIN:
US40637H1095
Market cap:
$5.82 billion
Shares in issue:
127.23 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Helen Torley
    President, Chief Executive Officer, Director
  • Nicole Labrosse
    Chief Financial Officer, Senior Vice President
  • Michael Labarre
    Senior Vice President, Chief Technical Officer
  • Mark Snyder
    Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.